Wednesday, September 25, 2013 9 AM - 11:30 AM
Columbus Club, Union Station - Washington, DC
Brand-name drug manufacturers have been accused of using controversial tactics to maintain market share after their patents expire. Critics contend that these actions—which include “pay for delay” agreements, rebates, and co-pay coupon programs prevent consumers and taxpayers from maximizing the savings associated with generic drugs.
Please join the AARP Public Policy Institute for a discussion of the impact of these efforts on consumers, taxpayer-funded programs like Medicare and Medicaid, and the drug industry. Experts with diverse perspectives will explore policy solutions that balance market oversight with incentives for brand-name drug manufacturers to innovate. Discussion will include a look at:
- What a recent Supreme Court ruling means for pay-for-delay agreements
- Whether the use of programs, such as co-pay coupons and rebates, stifle competition
- What to expect as more blockbuster drugs go off patent
Speakers and Panelists Include:
- Kristin Bass, Senior Vice President, Policy and Federal Government Affairs, Pharmaceutical Care Management Association (PCMA)
- Bruce Edgren, PharmD, RPh, Robert Wood Johnson Foundation Health Policy Fellow and Associate Professor and Chair, Department of Pharmacy Practice & Administration, University of Saint Joseph School of Pharmacy
- Richard Manning, PhD, Partner, Bates White, LLC and former executive at Pfizer and Merck & Co., Inc.
- Stephen Schondelmeyer, PharmD, PhD, Head, Department of Pharmaceutical Care & Health Systems, Endowed Chair in Pharmaceutical Management & Economics, Professor and Director, PRIME Institute, University of Minnesota
- Jamie Towey, Attorney, Health Care Division, Bureau of Competition, Federal Trade Commission
Discounts & Benefits
Next ArticleRead This